Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon

Abstract

The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer.

1 - 150 . (canceled) 
     
     
         151 . A method of treatment of cancer in bone in a subject and/or bone pain in a subject who has cancer in bone, comprising administering to the subject an effective amount of an interferon that comprises anti-cancer activity, wherein the interferon comprises an amino acid sequence of SEQ ID NO: 1. 
     
     
         152 . The method of  claim 151 , wherein the cancer in bone is a primary bone cancer, or a secondary bone cancer that metastasized from a primary tumor. 
     
     
         153 . The method of  claim 151 , wherein administering the interferon to the subject comprises administering the interferon by local administration. 
     
     
         154 . The method of  claim 153 , wherein the local administration of the interferon comprises administering the interferon to the cancerous lesion, or the interferon is administered by local administration to an area affected by cancer or comprising cancer cells. 
     
     
         155 . The method of  claim 153 , wherein local administration of the interferon comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration, and transmucosal administration. 
     
     
         156 . The method of  claim 153 , wherein administration of the interferon to the subject comprises administration of the interferon to or on the bone, the skin, the mucosa, and/or the submucosa of the subject, wherein the interferon comprises a concentration in a range of about 0.01 mg/ml to about 5 mg/ml. 
     
     
         157 . The method of  claim 153 , wherein the local administration of the interferon comprises administration by spraying. 
     
     
         158 . The method of  claim 155 , wherein application of interferon to the skin comprises application to or on the skin in proximity to the bone affected by cancer, or application to or on the skin surrounding the bone affected by cancer. 
     
     
         159 . The method of  claim 155 , wherein application of interferon to the mucosa comprises application to the mucosa in proximity to the bone affected by cancer, or application to the mucosa surrounding the bone affected by cancer. 
     
     
         160 . The method of  claim 153 , wherein local administration of the interferon comprises administration of interferon in a range of about 2 microgram to about 2100 microgram. 
     
     
         161 . The method of  claim 157 , wherein the administration of the interferon by spraying comprises administration of the interferon in an amount in a range of about 6 microgram to about 100 microgram per spray administration. 
     
     
         162 . The method of  claim 153 , wherein the interferon for local administration is formulated as at least one of: a dry powder, an aqueous solution, a cream, a membrane permeation or diffusion drug delivery system, a controlled release drug delivery system, a closed drug delivery system, a transdermal patch, or a depot comprising the interferon injected under the skin, for producing a slow-release effect. 
     
     
         163 . The method of  claim 153 , wherein the interferon comprises interferon formulated as nanoparticles, microparticles, microsphere, liposomes or a controlled release single or composite material. 
     
     
         164 . The method of  claim 153 , wherein administering the interferon to the subject further comprises administering the interferon by systemic administration and/or inhalation administration. 
     
     
         165 . The method of  claim 151 , further comprising administering to the subject at least one other anti-cancer therapy, wherein the at least one other anti-cancer therapy is administered to the subject before, at about the same time, and/or after administration of the interferon. 
     
     
         166 . The method of  claim 165 , wherein the at least one other anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, targeted therapy, and Traditional Chinese medicine. 
     
     
         167 . The method of  claim 166 , wherein the biotherapy comprises at least one of gene therapy and immunotherapy, and the surgical therapy comprises ablation therapy. 
     
     
         168 . A method of treatment of skin cancer, subcutaneous cancer, mucosal carcinoma and/or submucosal carcinoma and/or pain associated with the cancer in a subject, comprising administering to the subject an effective amount of an interferon that comprises anti-cancer activity, wherein the interferon comprises an amino acid sequence of SEQ ID NO: 1. 
     
     
         169 . The method of  claim 168 , wherein administering the interferon to the subject comprises administering the interferon by local administration. 
     
     
         170 . The method of  claim 169 , wherein local administration of the interferon comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration, and transmucosal administration. 
     
     
         171 . The method of  claim 170 , wherein application of interferon comprises application of the interferon percutaneously, on or to the skin of the subject, and/or transmucosally, to or on the mucosa of the subject. 
     
     
         172 . The method of  claim 169 , wherein the local administration of the interferon comprises administration by spraying. 
     
     
         173 . The method of  claim 169 , wherein administering the interferon to the subject further comprises administering the interferon by systemic administration and/or inhalation administration. 
     
     
         174 . The method of  claim 168 , further comprising administering to the subject at least one other anti-cancer therapy, wherein the at least one other anti-cancer therapy is administered to the subject before, at about the same time, and/or after administration of the interferon. 
     
     
         175 . A sprayer for administering an interferon that comprises anti-cancer activity and an amino acid sequence of SEQ ID NO:1, wherein the sprayer comprises the interferon formulated for local administration of the interferon. 
     
     
         176 . The sprayer of  claim 175 , wherein the interferon is formulated at a concentration in a range of at least about 0.01 mg/ml to about 5 mg/ml. 
     
     
         177 . The sprayer of  claim 176 , wherein the interferon is formulated at a concentration of about 0.3 mg/ml.